GILEAD SCIENCES, INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
GILEAD SCIENCES, INC. (GILD) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $186.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-26.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-02-26
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-12-31 was $29.00M, a 66.67% decline year-over-year.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-09-30 was $32.00M, a 81.50% decline year-over-year.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-06-30 was $38.00M.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2016-03-31 was $87.00M.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $186.00M, a 68.26% decline from fiscal 2015.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $586.00M, a 21.07% increase from fiscal 2014.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $484.00M, a 69.82% increase from fiscal 2013.
- GILEAD SCIENCES, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2013 was $285.00M, a 152.21% increase from fiscal 2012.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $29.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $61.00M derived: sum of 2 quarters · filed 2019-02-26 | $99.00M derived: sum of 3 quarters · filed 2019-02-26 | $186.00M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $32.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $70.00M derived: sum of 2 quarters · filed 2016-11-07 | $157.00M 10-Q · filed 2016-11-07 | $244.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $38.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $125.00M 10-Q · filed 2016-08-05 | $212.00M derived: sum of 3 quarters · filed 2018-02-27 | $385.00M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | $87.00M 10-Q · filed 2016-05-06 | $174.00M derived: sum of 2 quarters · filed 2018-02-27 | $347.00M derived: sum of 3 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $87.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $260.00M derived: sum of 2 quarters · filed 2018-02-27 | $586.00M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $173.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $499.00M 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | $326.00M 10-Q · filed 2015-08-05 | ||||
| 2014-12-31 | $484.00M 10-K · filed 2017-02-27 | ||||
| 2013-12-31 | $285.00M 10-K · filed 2016-02-24 | $284.65M 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $113.00M 10-K · filed 2015-02-25 | $112.63M 10-K · filed 2013-02-27 | |||
| 2011-12-31 | $37.23M 10-K · filed 2014-02-25 | ||||
| 2010-12-31 | $82.09M 10-K · filed 2013-02-27 | ||||
| 2009-12-31 | $88.37M 10-K · filed 2012-02-23 | ||||
| 2008-12-31 | $209.52M 10-K · filed 2011-02-28 | ||||
| 2007-12-31 | $110.68M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |